Comparative hazard identification by a single dose lung exposure of zinc oxide and silver nanomaterials in mice
Research output: Contribution to journal › Article › peer-review
Standard Standard
In: PLoS ONE, Vol. 10, No. 5, 01.05.2015, p. e0126934.
Research output: Contribution to journal › Article › peer-review
HarvardHarvard
APA
CBE
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - Comparative hazard identification by a single dose lung exposure of zinc oxide and silver nanomaterials in mice
AU - Gosens, Ilse
AU - Kermanizadeh, Ali
AU - Jacobsen, Nicklas Raun
AU - Lenz, Anke-Gabriele
AU - Bokkers, Bas
AU - de Jong, Wim H
AU - Krystek, Petra
AU - Tran, Lang
AU - Stone, Vicki
AU - Wallin, Håkan
AU - Stoeger, Tobias
AU - Cassee, Flemming R
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Comparative hazard identification of nanomaterials (NMs) can aid in the prioritisation for further toxicity testing. Here, we assessed the acute lung, systemic and liver responses in C57BL/6N mice for three NMs to provide a hazard ranking. A silver (Ag), non-functionalised zinc oxide (ZnO) and a triethoxycaprylylsilane functionalised ZnO NM suspended in water with 2% mouse serum were examined 24 hours following a single intratracheal instillation (I.T.). An acute pulmonary inflammation was noted (marked by a polymorphonuclear neutrophil influx) with cell damage (LDH and total protein) in broncho-alveolar lavage fluid (BALF) after administration of both non-functionalised and functionalised ZnO. The latter also induced systemic inflammation measured as an increase in blood neutrophils and a decrease in blood lymphocytes. Exposure to Ag NM was not accompanied by pulmonary inflammation or cytotoxicity, or by systemic inflammation. A decrease in glutathione levels was demonstrated in the liver following exposure to high doses of all three nanomaterials irrespective of any noticeable inflammatory or cytotoxic effects in the lung. By applying benchmark dose (BMD) modeling statistics to compare potencies of the NMs, we rank functionalised ZnO ranked the highest based on the largest number of affected endpoints, as well as the strongest responses observed after 24 hours. The non-functionalised ZnO NM gave an almost similar response, whereas Ag NM did not cause an acute response at similar doses.
AB - Comparative hazard identification of nanomaterials (NMs) can aid in the prioritisation for further toxicity testing. Here, we assessed the acute lung, systemic and liver responses in C57BL/6N mice for three NMs to provide a hazard ranking. A silver (Ag), non-functionalised zinc oxide (ZnO) and a triethoxycaprylylsilane functionalised ZnO NM suspended in water with 2% mouse serum were examined 24 hours following a single intratracheal instillation (I.T.). An acute pulmonary inflammation was noted (marked by a polymorphonuclear neutrophil influx) with cell damage (LDH and total protein) in broncho-alveolar lavage fluid (BALF) after administration of both non-functionalised and functionalised ZnO. The latter also induced systemic inflammation measured as an increase in blood neutrophils and a decrease in blood lymphocytes. Exposure to Ag NM was not accompanied by pulmonary inflammation or cytotoxicity, or by systemic inflammation. A decrease in glutathione levels was demonstrated in the liver following exposure to high doses of all three nanomaterials irrespective of any noticeable inflammatory or cytotoxic effects in the lung. By applying benchmark dose (BMD) modeling statistics to compare potencies of the NMs, we rank functionalised ZnO ranked the highest based on the largest number of affected endpoints, as well as the strongest responses observed after 24 hours. The non-functionalised ZnO NM gave an almost similar response, whereas Ag NM did not cause an acute response at similar doses.
KW - Animals
KW - Bronchoalveolar Lavage Fluid/chemistry
KW - Injections, Spinal
KW - Instillation, Drug
KW - Lung/drug effects
KW - Mice
KW - Mice, Inbred C57BL
KW - Nanostructures/administration & dosage
KW - Silver/administration & dosage
KW - Toxicity Tests/methods
KW - Zinc Oxide/administration & dosage
U2 - 10.1371/journal.pone.0126934
DO - 10.1371/journal.pone.0126934
M3 - Article
C2 - 25966284
VL - 10
SP - e0126934
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 5
ER -